Ardelyx, Inc.
NASDAQ:ARDXBiotechnology
Healthcare
$3.06 -1.03%
-$0.06 today
- Market cap
- $769.20M
- Beta
- 0.58
- P/E (TTM)
- -24.5
- EPS (TTM)
- -$0.24
52W Low $3.49High $8.40
Volume 3.39M
Average 3.58M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$42.48M
FY 2025 · Annual
Investing Cash Flow
-$8.96M
FY 2025 · Annual
Financing Cash Flow
$54.51M
FY 2025 · Annual
-48.9% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (158.17M) | (67.21M) | (66.07M) | (39.14M) | (61.6M) |
| Depreciation & Amortization | 1.44M | 1.14M | 1.29M | 2.06M | 3.06M |
| Deferred Income Tax | (190K) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 12.04M | 10.75M | 13.53M | 37.38M | 48.96M |
| Change in Working Capital | (11.92M) | (19.58M) | (43.39M) | (49.17M) | (31.35M) |
| Accounts Receivables | (502K) | (7.23M) | (14.3M) | (35.67M) | (14.14M) |
| Inventory | (10.37M) | (28.35M) | (21.14M) | (41.7M) | (31.92M) |
| Accounts Payables | (1.35M) | 6.58M | 279K | 4.86M | 3.24M |
| Other Working Capital | 300K | 9.42M | (8.23M) | 23.34M | 11.48M |
| Other Non-Cash Items | 4.25M | 4.84M | 4.91M | 4.05M | (1.55M) |
| Operating Cash Flow | (152.55M) | (70.04M) | (89.72M) | (44.81M) | (42.48M) |
| Capital Expenditures | (1.87M) | (55K) | (344K) | (1.01M) | (1.49M) |
| Acquisitions (Net) | (52.82M) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (72.74M) | (50.33M) | (215.23M) | (195.16M) | (218.92M) |
| Sales of Investments | 125.55M | 67M | 84.32M | 177.85M | 211.46M |
| Other Investing Activities | 52.82M | 1.8M | 0 | 0 | 0 |
| Investing Cash Flow | 50.95M | 18.42M | (131.25M) | (18.32M) | (8.96M) |
| Debt Repayment | (19.44M) | (6.07M) | 22.39M | 99.45M | 48.67M |
| Common Stock Issued | 101.15M | 71.63M | 119.24M | 8.14M | 5.84M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.3M | 9.78M | 4.67M | (1M) | 0 |
| Financing Cash Flow | 83M | 75.34M | 146.3M | 106.59M | 54.51M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (18.6M) | 23.71M | (74.67M) | 43.46M | 3.07M |
| Free Cash Flow | (154.42M) | (70.1M) | (90.06M) | (45.82M) | (43.98M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$61.6M
+ D&A$3.1M
+ Stock-Based Comp$49.0M
+ Deferred Tax$0
- Working Capital-$31.4M
- Other Non-Cash-$1.6M
= Operating Cash Flow-$42.5M
- Capex-$1.5M
= Free Cash Flow-$44.0M
Analysis
FY2025 free cash flow is -$44.0M. FCF conversion is 71.4% of net income. Operating cash flow was -$42.5M, with capex of -$1.5M. The largest bridge item is Stock-Based Comp at $49.0M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 3, 2026 | |
| 8-K | Current report | Nov 3, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 25, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 25, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 25, 2026 |
Does ARDX generate free cash flow?
Ardelyx, Inc. (ARDX) generated -$43.98M of free cash flow in fiscal 2025.
How much operating cash flow does ARDX produce?
Operating cash flow was -$42.48M, before capital expenditures of $1.49M.
Continue the stock analysis
Jump to another research area for this company.